GlassScriptPhysician profile
Peter Montan
NPI 1831801489
$3,303.99
in general payments reported to CMS, 2019-2025
28 companies · $2,022 in 2025
The $2,022 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $529 · 2024: $753 · 2025: $2,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,303.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $917.47 | 2024-2025 | Assure Wcd |
| Xeris Pharmaceuticals, INC. | $396.78 | 2025 | Recorlev, Gvoke Hypopen |
| Amgen INC. | $317.99 | 2023-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $233.33 | 2025 | Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $190.16 | 2023-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.58 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $136.99 | 2023-2025 | Farxiga, Lokelma, Wainua |
| Astellas Pharma US INC | $103.92 | 2025 | Veozah |
| Janssen Pharmaceuticals, INC | $103.18 | 2023-2024 | Xarelto |
| Lilly USA, LLC | $84.90 | 2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $81.87 | 2023-2024 | Verquvo |
| Exact Sciences Corporation | $78.24 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ardelyx, INC. | $77.31 | 2025 | Ibsrela |
| Abiomed | $71.09 | 2025 | |
| Phathom Pharmaceuticals, INC. | $50.32 | 2025 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $47.16 | 2025 | |
| Pfizer INC. | $47.03 | 2025 | |
| Abbvie INC. | $29.14 | 2025 | |
| Shield Therapeutics INC | $25.66 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $23.10 | 2023 | Inpefa |
| Glaxosmithkline, LLC. | $21.35 | 2025 | Trelegy Ellipta |
| Hologic Sales and Service, LLC | $19.45 | 2025 | Aptima |
| Novartis Pharmaceuticals Corporation | $19.37 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $16.99 | 2025 | Camzyos |
| Chiesi USA, INC. | $15.71 | 2023 | Kengreal, Cleviprex |
| Cvrx, INC. | $15.34 | 2025 | Barostim Neo System |
| Daiichi Sankyo INC. | $13.89 | 2023 | Injectafer |
| Baxter Healthcare | $13.67 | 2024 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Montan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.